Ligand Pharmaceuticals Incorporated (LGND)

Etorro trading 970x250
Ligand Pharmaceuticals Incorporated (LGND) Logo

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company’s commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company’s partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California. Address: 3911 Sorrento Valley Boulevard, San Diego, CA, United States, 92121

Ligand Pharmaceuticals Incorporated News and around…

Latest news about Ligand Pharmaceuticals Incorporated (LGND) common stock and company :

Week in Review: China's Hansoh Signs Two siRNA Deals Worth $1.7 Billion
23 Oct, 2021 FinancialContent

Deals and Financings  Hansoh, a Jiangsu Province biopharma, announced a $1.3 billion deal to develop three siRNA candidates from London's Silence Therapeutics following last week's $456 million deal with Korea's OliX for rights to three other siRNA molecules; Hangzhou Microtech Medical staged a $233 million IPO on the Hong Kong Exchange to support its portfolio of diabetes care products; ShouTi, a San Francisco-Shanghai biopharma, closed a $100 million Series B round for its computational and structure-based discovery platform; Chase Therapeutics, a Washington, DC  pharma, completed a milestone-based $20 million Series B financing led by Chinalink Asia Holdings of Hong Kong; Shanghai Antengene formed a research collaboration with Korea's LegoChem to generate antibody drug conjugate candidates; China Resources Double-Crane Pharma acquired Asia rights to a novel oral COVID-19 antiviral therapeutic developed by California's Ligand Pharma;  Trials and Approvals  Shanghai Zai Lab reported positive results from a Phase III trial of a novel antibacterial for Acinetobacter baumannii infections; Suzhou Innovent reported its PD-1 inhibitor met its progression free survival endpoint in the first interim analysis of Phase III NSCLC trial data; Suzhou Kintor Pharma was approved to start a Phase I China trial of its dual-targeting PD-L1/TGF-β antibody in advanced solid tumors; United BioPharma of Taiwan will start a Taiwan-China clinical trial of its novel long-acting treatment for genital herpes caused by simplex viruses 1 and 2;  Company News  Shanghai I-Mab will build a San Diego laboratory focusing on translational medicine and formulation research.  Stock Symbols: (HK: 3692) (AIM/NSDQ: SLN) (HK: 2236) (HK: 6996) (KOSDAQ: 141080) (NSDQ: LGND) (NSDQ: ZLAB; HKEX: 9688) (HK: 01801) (HK: 9939) Share this with colleagues:

Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for
22 Oct, 2021 Yahoo! Finance

Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ligand Outlicenses BEPro Tech To Develop Oral COVID-19 Antivirals
21 Oct, 2021 FinancialContent

Ligand Pharmaceuticals Incorporated(NASDAQ: LGND) has signed a collaboration agreement withDouble-Crane Pharmaceutical Co ...

Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™
21 Oct, 2021 FinancialContent

Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic using Ligand’s BEPro Technology™

Double-Crane In-Licenses Asia Rights to Oral COVID-19 Antiviral
21 Oct, 2021 FinancialContent

China Resources Double-Crane Pharma acquired Asia rights to a novel oral COVID-19 antiviral therapeutic compound developed by California's Ligand Pharma. The candidate was discovered using Ligand's BEPro proprietary prodrug technology that is aimed at nucleotides and nucleotide analogs. Ligand says the technology produces candidates with improved efficacy and safety profiles. CRDC, which will be responsible for all costs for developing the antiviral in Asia, will make an upfront payment to Ligand, plus pay milestones and tiered royalties on net sales. More details.... Stock Symbol: (NSDQ: LGND) Share this with colleagues:

Helping Your Kid Pay for College? Check Out This Podcast.
19 Oct, 2021 FinancialContent

And a look at stocks that provided great lessons.

Has Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
27 Sep, 2021 Yahoo! Finance

Ligand Pharmaceuticals' (NASDAQ:LGND) stock is up by a considerable 22% over the past month. As most would know...

Ligand Pharmaceuticals Stock Shows Rising Price Performance
22 Sep, 2021 Yahoo! Finance

A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance.

Ligand Pharmaceuticals Shows Rising Price Performance With Jump To 81 RS Rating
22 Sep, 2021 FinancialContent

A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance.

Ligand Pharmaceuticals Stock Shows Market Leadership With Jump To 82 RS Rating
20 Sep, 2021 Yahoo! Finance

A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance.

Ligand Pharmaceuticals Shows Market Leadership With Jump To 82 RS Rating
20 Sep, 2021 FinancialContent

A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance.

Stock Upgrades: Ligand Pharmaceuticals Shows Rising Relative Strength
15 Sep, 2021 FinancialContent

Ligand Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

InvestorNewsBreaks – Digital Turbine Inc. (NASDAQ: APPS) Featured in Simply Wall St Journal
02 Sep, 2021 FinancialContent
Noteworthy Tuesday Option Activity: LGND, CZR, NUE
31 Aug, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Ligand Pharmaceuticals Inc (LGND), where a total volume of 909 contracts has been traded thus far today, a contract volume which is representative of approximately 90,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 53.9% of LGND's average daily trading volume over the past month, of 168,540 shares..

Why Digital Turbine's Stock Is Trading Higher Today
31 Aug, 2021 FinancialContent

Digital Turbine Inc (NASDAQ: APPS) is trading higher Tuesday afterit was announced the company is set to join the S&P MidCap ...

Why Digital Turbine Stock Was Flying Higher Today
31 Aug, 2021 FinancialContent

The company is leaving small-cap stocks behind and being added to the mid-cap ranks.

Digital Turbine Added To S&P MidCap 400 Index
31 Aug, 2021 FinancialContent

Media and mobile communications companyDigital Turbine Inc(NASDAQ: APPS)will replaceLigand Pharmaceuticals ...

The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
31 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Performance Food Group & Digital Turbine Set to Join S&P MidCap 400; TreeHouse Foods & Ligand Pharmaceuticals to Join S&P SmallCap 600
30 Aug, 2021 Yahoo! Finance

S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600:

Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
30 Aug, 2021 FinancialContent

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Gloria Biosciences (GloriaBio) has received approval from China’s National Medical Products Administration (NMPA) for zimberelimab (GLS-010), an OmniAb-derived anti-PD-1 monoclonal antibody for the treatment of recurrent or refractory classical Hodgkin’s lymphoma (cHL). GloriaBio has development and commercialization rights in China with respect to zimberelimab through a sublicense agreement with Ligand's licensee Wuxi Biologics Ireland Limited.

Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
16 Aug, 2021 FinancialContent

Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

Sermonix Pharmaceuticals Completes Enrollment of Phase 2 ELAINE 1 Randomized Clinical Trial Assessing Efficacy of Oral Lasofoxifene Versus Intramuscular Fulvestrant
16 Aug, 2021 FinancialContent

The study enrolled 100 patients who have ER+/HER2- breast cancer with an ESR1 mutation, with topline data expected in first half of 2022

What To Know About Rand Paul Failing To Disclose Gilead Stock Purchase For 16 Months
12 Aug, 2021 FinancialContent

Stock transactions by members of the U.S. Congress and their spouses have been a hot topic over the last several years. A transaction ...

New Strong Sell Stocks for August 5th
05 Aug, 2021 Yahoo! Finance

AZRX, GHL, HEES, LGND, and POLY have been added to the Zacks Rank #5 (Strong Sell) List on August 5, 2021.

Ligand (LGND) Q2 Earnings & Sales Beat, 2021 Guidance Cut
30 Jul, 2021 Yahoo! Finance

Ligand (LGND) reports encouraging second-quarter 2021 numbers by beating estimates on both counts.

Analysts See 12% Upside For The Holdings of IVOG
30 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard S&P Mid-Cap 400 Growth ETF (IVOG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $226.21 per unit.

Ligand Pharmaceuticals Incorporated (LGND) Q2 2021 Earnings Call Transcript
30 Jul, 2021 FinancialContent

LGND earnings call for the period ending June 30, 2021.

Ligand Pharmaceuticals (LGND) Q2 Earnings and Revenues Top Estimates
29 Jul, 2021 Yahoo! Finance

Ligand (LGND) delivered earnings and revenue surprises of 12.41% and 15.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Ligand Reports Second Quarter 2021 Financial Results
29 Jul, 2021 FinancialContent

Ligand Reports Second Quarter 2021 Financial Results

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
29 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Ligand Pharmaceuticals Incorporated (LGND) is a NASDAQ Common Stock listed in , ,

970x250